Advanced search

Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab

Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
Schats, Kelly, Emily A Van Vre, Isolde Debyser, Arno Vandenbroeck, Yanina Jansen, Teofila Seremet, Koen Marien, et al. 2017. “Immune Cell Profiling of Melanoma Metastases from Patients Treated with TriMixDC-MEL Dendritic Cell Therapy in Combination with Ipilimumab.” In Journal of Clinical Oncology. Vol. 35.
APA
Schats, K., Van Vre, E. A., Debyser, I., Vandenbroeck, A., Jansen, Y., Seremet, T., Marien, K., et al. (2017). Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab. JOURNAL OF CLINICAL ONCOLOGY (Vol. 35). Presented at the Annual meeting of the American Society of Clinical Oncology (ASCO).
Vancouver
1.
Schats K, Van Vre EA, Debyser I, Vandenbroeck A, Jansen Y, Seremet T, et al. Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab. JOURNAL OF CLINICAL ONCOLOGY. 2017.
MLA
Schats, Kelly, Emily A Van Vre, Isolde Debyser, et al. “Immune Cell Profiling of Melanoma Metastases from Patients Treated with TriMixDC-MEL Dendritic Cell Therapy in Combination with Ipilimumab.” Journal of Clinical Oncology. Vol. 35. 2017. Print.
@inproceedings{8557769,
  articleno    = {abstract e21030},
  author       = {Schats, Kelly and Van Vre, Emily A and Debyser, Isolde and Vandenbroeck, Arno and Jansen, Yanina and Seremet, Teofila and Marien, Koen and Fransen, Erik and Schrijvers, Dorien and Van Criekinge, Wim and Thielemans, Kris and Neyns, Bart and De Meester, Ingrid and Kockx, Mark},
  booktitle    = {JOURNAL OF CLINICAL ONCOLOGY},
  issn         = {0732-183X},
  language     = {eng},
  location     = {Chicago, IL, USA},
  number       = {suppl. 15},
  title        = {Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab},
  url          = {http://dx.doi.org/10.1200/JCO.2017.35.15\_suppl.e21030},
  volume       = {35},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: